NEW YORK (GenomeWeb News) – Bruker said today that a member of the Laukien family sold two million of the company's shares in a block trade, and that CEO Frank Laukien bought 100,000 shares from the same family member in a private transaction.

The life science and environmental research tools maker, which now has a public float of 50.9 million shares, said that the unidentified Laukien family member is not involved in the company's business. The aggregate number of shares sold yesterday amounts to 12.6 percent of the selling shareholder's ownership.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.